A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).

被引：0
|
作者：
Schadendorf, Dirk
Ascierto, Paolo Antonio
Espinosa, Enrique
Haanen, John B. A. G.
Hermann, Frank
Nathan, Paul D.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Ist Nazl Tumori Fdn Pascale, Naples, Italy
[3] Univ Autonoma Madrid, Hosp Univ La Paz, Madrid, Spain
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Bristol Myers Squibb, Munich, Germany
[6] Mt Vernon Canc Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9083
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial
    Fujimoto, Daichi
    Yomota, Makiko
    Sekine, Akimasa
    Morita, Mitsunori
    Morimoto, Takeshi
    Hosomi, Yukio
    Ogura, Takashi
    Tomioka, Hiromi
    Tomii, Keisuke
    LUNG CANCER, 2019, 134 : 274 - 278
  • [42] EFFICACY AND SAFETY OF IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA WHO HAD PROGRESSED ON ONE OR MORE PRIOR THERAPIES: RESULTS FROM A SINGLE-ARM, MULTICENTER STUDY
    Maio, M.
    Hoos, A.
    Ibrahim, R.
    Gajewski, T.
    Pehamberger, H.
    Wolchok, J.
    O'Day, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 241
  • [43] A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).
    Amin, Asim
    Lawson, David H.
    Salama, April K.
    Koon, Henry B.
    Guthrie, Troy H.
    Thomas, Sajeve Samuel
    O'Day, Steven
    Shaheen, Montaser F.
    Zhang, Bin
    Francis, Stephen
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [45] Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
    Si, Lu
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Wei, Xiaoting
    Sun, Peng
    Jia, Zhongwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) plus ipilimumab (ipi) or nivo plus chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.
    Moehler, Markus H.
    Janjigian, Yelena Yuriy
    Adenis, Antoine
    Aucoin, Jean-Sebastien
    Boku, Narikazu
    Chau, Ian
    Cleary, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Clinical efficacy and safety of nivolumab in malignant non-pleural mesothelioma: A multicenter, open-label, single-arm, Japanese phase II trial (VIOLA) protocol
    Kuribayashi, Kozo
    Igeta, Masataka
    Daimon, Takashi
    Maede, Ibu
    Suna, Shinichiro
    Okamoto, Rika
    Kijima, Takashi
    ONCOLOGY, 2023, 101 (04) : 257 - 261
  • [48] Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study
    Jin, Jie
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Zhou, Hu
    Gao, Sujun
    Wang, Wei
    Dang, Huibing
    Chen, Yuqing
    Wang, Jishi
    Zhao, Peng
    Yang, Haiping
    Ma, Liangming
    Zhao, Qingwei
    Suo, Shanshan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Song, Zhengbo
    Lou, Guangyuan
    Wang, Yina
    Yang, Zhiping
    Wang, Wenxian
    Ji, Yongling
    Chen, Shiqing
    Xu, Chunwei
    Hu, Xiao
    Zhang, Yiping
    BMC MEDICINE, 2022, 20 (01)
  • [50] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Zhengbo Song
    Guangyuan Lou
    Yina Wang
    Zhiping Yang
    Wenxian Wang
    Yongling Ji
    Shiqing Chen
    Chunwei Xu
    Xiao Hu
    Yiping Zhang
    BMC Medicine, 20
12345